Evidence map›Paper›PMID 40635380›Full record

ArticleAnnals of medicine2025

Soluble programmed cell death ligand-1 as a predictive biomarker for severity and poor prognosis in pulmonary tuberculosis.

Xiaojue Wang, Weibing Lin, Huimin Li, Sibo Long, Jun Yan, Yiheng Shi, Hongtao Zhang, Xinting Yang, Ling Yi, Guirong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaojue WangDepartment of Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Weibing LinDepartment of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Huimin LiDepartment of Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0009-0005-9533-746X
Sibo LongDepartment of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Jun YanDepartment of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yiheng ShiDepartment of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Hongtao ZhangDepartment of Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Xinting YangTuberculosis Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Ling YiDepartment of Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0001-6028-455X
Guirong WangDepartment of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to assess whether soluble programmed death-ligand 1 (sPD-L1) could serve as a new biomarker for PTB.

methodsPlasma sPD-L1 levels in the discovery cohort were analyzed through flow cytometry and validated by sandwich ELISA. Pleural effusion sPD-L1 levels were measured using ELISA.

resultsIn the discovery cohort, sPD-L1 levels in the severe (SE,

conclusionElevated plasma sPD-L1 may be a predictive marker for both disease severity and poor prognosis in PTB patients. Pleural effusion sPD-L1 levels might potentially function as an adjunctive marker for differentiating TPE from MPE.

Indexed as

B7-H1 AntigenPleural EffusionTuberculosis, PulmonaryAdultAgedBiomarkersEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansMaleMiddle AgedPredictive Value of TestsPrognosisROC CurveSeverity of Illness IndexB7-H1 AntigenBiomarkersCD274 protein, humanpredictive markerprognosisIntroductionPulmonary tuberculosisseveritysPD-L1

Identifiers

PMID40635380
PMCPMC12247086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.